Abstract: A polarizing plate and a display device including the same are provided. A polarizing plate includes a polarizer comprising an absorption axis and a transmission axis that intersect each other, a first retardation layer disposed on a surface of the polarizer, and a second retardation layer disposed on another surface opposite to the surface of the polarizer. An in-plane retardation value of the second retardation layer is greater than about 20 nm and less than about 100 nm. An angle between the absorption axis of the polarizer and a retardation axis of the second retardation layer is in a range of about 10° to about 45°.

Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. (In the above, A, B and R, and the like are the same as defined in the description of the invention.

Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Abstract: The present disclosure provides androgen receptor (AR) and phosphodiesterase 5 (PDE-5) inhibitor compounds of the formula (I): and compositions including said compounds. The compounds can provide dual functionality for inhibiting AR and inhibiting PDE-5. The present disclosure also provides methods of using said compounds and compositions for inhibiting AR and PDE-5 in a biological system or biological sample. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. (In the above, A, B and R, and the like are the same as defined in the description of the invention.

Abstract: A method of protecting a kidney by reducing contrast media-induced nephrotoxicity or for preventing or treating contrast media-induced acute kidney injury is disclosed.

Abstract: Disclosed is an oligonucleotide-modified nucleic acid containing at least one 1-?-D-arabinofuranosylcytosine as a modified nucleic acid having therapeutic efficacies and guanosine. More particularly, a novel oligonucleotide-modified nucleic acid containing at least one modified nucleic acid (N) having therapeutic efficacies and being rich in guanosine (G) is synthesized and the fact that the novel oligonucleotide-modified nucleic acid has excellent apoptotic activities on blood cancer cells and drug-resistant blood cancer cells is identified. Based on this, provided is a composition for preventing, ameliorating or treating blood cancer, containing the novel oligonucleotide-modified nucleic acid, and the novel oligonucleotide-modified nucleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present disclosure provides adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson’s disease.

Abstract: A method of preparing super absorbent polymer includes carrying out a crosslinking polymerization of a monomer mixture comprising a water-soluble ethylenically unsaturated monomer having at least partially neutralized acidic groups, a forming agent, a foam-promoting agent and a silicone-based surfactant in the presence of an internal crosslinking agent to form a hydrogel polymer; drying, pulverizing and classifying the hydrogel polymer to form a base polymer powder; and further crosslinking a surface of the base polymer powder in the presence of a surface crosslinking agent to form a surface crosslinked layer. The method produces super absorbent polymer having not only an excellent absorbent capacity and an absorbency under load but also the rewetting phenomenon can be effectively prevented.

Abstract: A pharmaceutical composition or an antiviral agent for the treatment of pulmonary fibrosis is disclosed. The composition or the antiviral agent contains a compound of Formula 1, which is a pyrazole derivative, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a method for preparing a superabsorbent polymer, and a superabsorbent polymer prepared thereby. A superabsorbent polymer prepared by the preparation method exhibits minimized deterioration of physical properties after being pulverized, and thus basic absorbance performance is excellent and an excellent liquid permeability and absorbance rate can be exhibited.

Abstract: The present invention provides a novel pyrazole derivative compound represented by Chemical formula I or a salt thereof, and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to an ophthalmic preparation containing an active ingredient selected from 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol compound or a pharmaceutically acceptable salt thereof. The eye drop according to the present invention is excellent in stability and safety and shows an excellent effect on prevention or treatment of eye diseases in such a way that an active ingredient thereof reaches a posterior segment of an eyeball simply through instillation rather than a direct injection into an eyeball.

Abstract: The present disclosure provides phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase (sGC) via donation of nitrogen oxide (NO) from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of protein kinase G (PKG). The compounds and compositions find use in therapeutic applications including in the treatment of a variety of eye diseases.

Abstract: The present invention relates to a method for preparing spherical cured polymer particles from a curable composition. The method comprises the steps of: dropping a curable composition onto a substrate having a water contact angle of 150° to 170° at 25° C. to form droplets of the curable composition; and curing the droplets to form the polymer particles.

Abstract: The present invention relates to a composition for treating eye diseases, wherein the composition comprises a pyrazole-based compound, which is a pharmacologically active substance, and a biodegradable polymer, so that a drug effectively reaches a posterior segment of an eyeball, while prolonging an action time of the drug administered into the eyeball.

Abstract: A super absorbent polymer according to the present invention has an excellent discoloration resistance property even under high temperature/high humidity conditions, while maintaining excellent absorption performance, and is preferably used for hygienic materials such as diapers, and thus can exhibit excellent performance.

Abstract: The present disclosure provides androgen receptor (AR) and phosphodiesterase 5 (PDE-5) inhibitor compounds and compositions including said compounds. The compounds can provide dual functionality for inhibiting AR and inhibiting PDE-5. The present disclosure also provides methods of using said compounds and compositions for inhibiting AR and PDE-5 in a biological system or sample. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.

Abstract: The present invention relates to a super absorbent polymer having not only excellent absorption rate and absorbency under load but also excellent rewetting properties, and a method for preparing the same.